Trial Profile
HYPAZ: An Open-label Investigation Into Hypertension Induced by Pazopanib Therapy
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 28 Nov 2023
Price :
$35
*
At a glance
- Drugs Pazopanib (Primary)
- Indications Advanced breast cancer; Carcinoma; Cervical cancer; Gastrointestinal cancer; Glioblastoma; Malignant melanoma; Non-small cell lung cancer; Ovarian cancer; Pancreatic cancer; Prostate cancer; Renal cell carcinoma; Skin cancer; Small cell lung cancer; Soft tissue sarcoma; Uveal melanoma
- Focus Adverse reactions
- Acronyms HYPAZ
- 20 Jul 2015 Planned End Date changed from 1 Sep 2018 to 1 Sep 2015 as per ClinicalTrials.gov record.
- 20 Jul 2015 Status changed from completed to discontinued as per ClinicalTrials.gov record..
- 18 Oct 2014 Status changed from recruiting to completed as reported by United Kingdom Clinical Research Network.